TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty pharmaceutical company focused on central nervous system (CNS) disorders, announced today the Company will present at the OneMedForum San Francisco 2011 at 10:15 am PT on January 11, 2011, at the Sir Francis Drake Hotel in San ... read more

Jan. 4, 2011--Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Kent Snyder, the Company’s Chief Executive Officer, and Tony Rogers, Vice President ... read more

Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced today that Chief Executive Officer Victor Viegas and Chief Financial Officer Shum Mukherjee will present to the investment community at the 13th Annual Needham Growth Conference on ... read more

Immunome, a discovery-stage company with a proprietary native human monoclonal antibody (N-huMAb) discovery platform, has been selected to present at two major emerging life science finance conferences in San Francisco occurring simultaneously with the JP Morgan Healthcare Conference, the world’s largest annual healthcare ... read more

AMRI (NASDAQ: AMRI) announced today a research and licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for a family of antibacterial compounds discovered from AMRI’s proprietary research of its natural products sample collection. ... read more

Bio-Path Holdings, Inc. (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase™ 2011 Conference in San Francisco, Calif., on Tuesday, ... read more

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it has appointed Mark O. Thornton, M.D., Ph.D., Executive Vice President and Chief Development Officer. In this position, Dr. Thornton will be responsible for the oversight of all disciplines involved in the product development process and will report ... read more

Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the company's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, on January 11, 2011. The live webcast is scheduled to begin at 4 p.m. PT and will feature an overview of the company by ... read more

Life Technologies Corporation (NASDAQ: LIFE) today announced it will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 8:00 a.m. PST. Greg Lucier, Life Technologies’ Chairman and Chief Executive Officer, will present on behalf of the company. The company will webcast ... read more

Drug Discovery News (ddn), a news organization covering issues, trends and product news in the pharmaceutical drug development and discovery industry, recently conducted exclusive interviews with the lead plaintiffs in the controversial Sherley v. Sebelius lawsuit challenging President Barack Obama’s order granting ... read more

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that, in partnership with The New England Patriots Radio Network, 985 The Sports Hub, it has selected Melissa Chen, a science teacher at the Lowell Middlesex Academy Charter School, to receive the Cubist Pharmaceuticals ... read more

The Biotechnology Industry Organization (BIO) announced today that media registration for the 2011 BIO International Convention is now available online. Hosted by BIO, the global event for biotechnology will be held June 27-30, 2011 at the Walter E. Washington Convention ... read more

Start-up company ImmuVen and the University of Illinois Urbana-Champaign have entered into a license agreement under which ImmuVen will develop modified T cell receptor proteins for the purpose of treating cancer and methicillin-resistant Staphylococcus aureus (MRSA). ImmuVen was co-founded by Dr. David Kranz of the University ... read more

OncoMed Pharmaceuticals CEO Paul Hastings will serve another term as Chairman of the Board of BayBio, Northern California’s life sciences association. In addition, the trade association also announced the appointment of Stanford University’s Michael Alvarez as chair of the BayBio Institute. ... read more

BioMarker Strategies announced today that it has appointed three new Directors, including Dr. Samuel Broder, who is a former Director of the National Cancer Institute and Chief Medical Officer at Celera; Dr. Mark Velleca, a founder and former Senior VP of CGI Pharmaceuticals; and, Dr. Paul ... read more

BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led ... read more

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s lead drug candidate SNS01-T for treatment of multiple myeloma. As a result, the company is eligible to receive ... read more

Jan. 3, 2011--Senomyx, Inc. (NASDAQ:SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has entered into a new collaborative agreement with Cadbury Adams USA LLC, a unit ... read more

CenterWatch today reports that the fragmented U.S. investigative site market is poised for acquisitions that may be driven by the most unlikely of sources: large European site management organizations (SMOs). The report, released in the January issue of The CenterWatch Monthly, provides an in-depth look at ... read more

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into a $25 million non-convertible stock purchase agreement with Socius CG II, Ltd. , a subsidiary of Socius Capital Group (“Socius”). Socius, based in New ... read more